Schedule 13G ownership disclosure
Spero Therapeutics Inc
Security class unavailable · CUSIP: 84833T103
Event date: 2021-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,376,968
- Percent of class
- 4.2600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-22-007249
- Form type
- SC 13G
- Filer
- Atlas Venture Fund IX, L.P.
- CIK
- CIK 1671219
- Filed
- Jan 25, 2022
- Reporting period
- Dec 31, 2021
- Description
- Schedule 13G beneficial ownership